• Submit to JPM Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [275 KB]
• Full-Text XML
• Article Versions Notes
• Supplement File 1

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Piatkov, I
• Jones, T
• McLean, M
• [+] on Google Scholar
• Piatkov, I
• Jones, T
• McLean, M
• [+] on PubMed
• Piatkov, I
• Jones, T
• McLean, M

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

J. Pers. Med. 2012, 2(4), 149-157; doi:10.3390/jpm2040149

Case Report

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics

Irina Piatkov* , Trudi Jones and Mark McLean

University of Western Sydney Clinic and Research Centre Blacktown, Western Sydney Local Health District, Blacktown 2148, NSW, Australia

* Author to whom correspondence should be addressed.

Received: 24 August 2012; in revised form: 21 September 2012 / Accepted: 21 September 2012 / Published: 1 October 2012

(This article belongs to the Special Issue Untold Stories about Personalized Medicine: If You Thought Personalized Medicine Is for Others to Worry about, Think Again)

Download PDF Full-Text [275 KB, uploaded 1 October 2012 11:16 CEST]

Abstract: Thousands of samples for pharmacogenetic tests have been analysed in our laboratory since its establishment. In this article we describe some of the most interesting cases of CYP poor metabolisers associated with adverse reactions to psychotropic drugs. Prevention of disease/illness, including Adverse Drug Reaction (ADR), is an aim of modern medicine. Scientific data supports the fact that evaluation of drug toxicology includes several factors, one of which is genetic variations in pharmacodynamics and pharmacokinetics of drug pathways. These variations are only a part of toxicity evaluation, however, even if it would help to prevent only a small percentage of patients from suffering adverse drug reactions, especially life threatening ADRs, pharmacogenetic testing should play a significant role in any modern psychopharmacologic practice. Medical practitioners should also consider the use of other medications or alternative dosing strategies for drugs in patients identified as altered metabolisers. This will promise not only better and safer treatments for patients, but also potentially lowering overall healthcare costs.

Keywords: venlafaxine; nortriptyline; suicide; adverse effects; genetic polymorphisms; cytochrome P450; pharmacogenetics

Supplementary Files

• Supplementary File 1:

  PDF-Document (PDF, 182 KB)

Article Statistics

Cite This Article